APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologic Drugs Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchBiologic Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologic Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Biologic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologic Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologic Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Biologic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologic Drugs market include Abbott Laboratories, Amgen, Amgen, Pfizer, Eli Lilly, Roche, Merck & Co., Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologic Drugs Segment by Company

Abbott Laboratories

Amgen

Amgen

Pfizer

Eli Lilly

Roche

Merck & Co.

Novartis

Johnson & Johnson

Sanofi

Biologic Drugs Segment by Type

Humira

Avastin

Enbrel

Herceptin

Lantus

Remicade

Rituxan

Others

Biologic Drugs Segment by Application

Auto-Immune Diseases

Inflammation

Blood Diseases

Cardiovascular Diseases

Diabetes

Others

Biologic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologic Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biologic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Biologic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologic Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologic Drugs industry.

Chapter 3: Detailed analysis of Biologic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologic Drugs Industry Trends Table 2. Biologic Drugs Industry Drivers Table 3. Biologic Drugs Industry Opportunities and Challenges Table 4. Biologic Drugs Industry Restraints Table 5. Global Biologic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologic Drugs Revenue Share by Company (2021-2026) Table 7. Global Biologic Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biologic Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Biologic Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Biologic Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biologic Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Biologic Drugs Company, Product Type & Application Table 13. Global Biologic Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Humira Table 18. Significant Companies of Avastin Table 19. Significant Companies of Enbrel Table 20. Significant Companies of Herceptin Table 21. Significant Companies of Lantus Table 22. Significant Companies of Remicade Table 23. Significant Companies of Rituxan Table 24. Significant Companies of Others Table 25. Global Biologic Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Biologic Drugs Sales Volume by Type (2021-2026) & (K Units) Table 27. Global Biologic Drugs Sales Volume by Type (2027-2032) & (K Units) Table 28. Global Biologic Drugs Sales Volume Share by Type (2021-2026) Table 29. Global Biologic Drugs Sales Volume Share by Type (2027-2032) Table 30. Global Biologic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Biologic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Biologic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Biologic Drugs Sales Value Share by Type (2021-2026) Table 34. Global Biologic Drugs Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Auto-Immune Diseases Table 36. Significant Companies of Inflammation Table 37. Significant Companies of Blood Diseases Table 38. Significant Companies of Cardiovascular Diseases Table 39. Significant Companies of Diabetes Table 40. Significant Companies of Others Table 41. Global Biologic Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Biologic Drugs Sales Volume by Application (2021-2026) & (K Units) Table 43. Global Biologic Drugs Sales Volume by Application (2027-2032) & (K Units) Table 44. Global Biologic Drugs Sales Volume Share by Application (2021-2026) Table 45. Global Biologic Drugs Sales Volume Share by Application (2027-2032) Table 46. Global Biologic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Biologic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 48. Global Biologic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 49. Global Biologic Drugs Sales Value Share by Application (2021-2026) Table 50. Global Biologic Drugs Sales Value Share by Application (2027-2032) Table 51. Global Biologic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 52. Global Biologic Drugs Sales by Region (2021-2026) & (K Units) Table 53. Global Biologic Drugs Sales Market Share by Region (2021-2026) Table 54. Global Biologic Drugs Sales by Region (2027-2032) & (K Units) Table 55. Global Biologic Drugs Sales Market Share by Region (2027-2032) Table 56. Global Biologic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Biologic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 58. Global Biologic Drugs Sales Value Share by Region (2021-2026) Table 59. Global Biologic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 60. Global Biologic Drugs Sales Value Share by Region (2027-2032) Table 61. Global Biologic Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 62. Global Biologic Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 63. Global Biologic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 64. Global Biologic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Biologic Drugs Sales by Country (2021-2026) & (K Units) Table 66. Global Biologic Drugs Sales Market Share by Country (2021-2026) Table 67. Global Biologic Drugs Sales by Country (2027-2032) & (K Units) Table 68. Global Biologic Drugs Sales Market Share by Country (2027-2032) Table 69. Global Biologic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 70. Global Biologic Drugs Sales Value Market Share by Country (2021-2026) Table 71. Global Biologic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 72. Global Biologic Drugs Sales Value Market Share by Country (2027-2032) Table 73. Abbott Laboratories Company Information Table 74. Abbott Laboratories Business Overview Table 75. Abbott Laboratories Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Abbott Laboratories Biologic Drugs Product Portfolio Table 77. Abbott Laboratories Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amgen Biologic Drugs Product Portfolio Table 82. Amgen Recent Development Table 83. Amgen Company Information Table 84. Amgen Business Overview Table 85. Amgen Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Amgen Biologic Drugs Product Portfolio Table 87. Amgen Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Pfizer Biologic Drugs Product Portfolio Table 92. Pfizer Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Eli Lilly Biologic Drugs Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Roche Company Information Table 99. Roche Business Overview Table 100. Roche Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Roche Biologic Drugs Product Portfolio Table 102. Roche Recent Development Table 103. Merck & Co. Company Information Table 104. Merck & Co. Business Overview Table 105. Merck & Co. Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Merck & Co. Biologic Drugs Product Portfolio Table 107. Merck & Co. Recent Development Table 108. Novartis Company Information Table 109. Novartis Business Overview Table 110. Novartis Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Novartis Biologic Drugs Product Portfolio Table 112. Novartis Recent Development Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson Biologic Drugs Product Portfolio Table 117. Johnson & Johnson Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Biologic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sanofi Biologic Drugs Product Portfolio Table 122. Sanofi Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Biologic Drugs Distributors List Table 126. Biologic Drugs Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Biologic Drugs Product Image Figure 2. Global Biologic Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biologic Drugs Sales (2021-2032) & (K Units) Figure 5. Global Biologic Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Biologic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Humira Image Figure 10. Avastin Image Figure 11. Enbrel Image Figure 12. Herceptin Image Figure 13. Lantus Image Figure 14. Remicade Image Figure 15. Rituxan Image Figure 16. Others Image Figure 17. Global Biologic Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Biologic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Biologic Drugs Sales Volume Share by Type (2021-2032) Figure 20. Global Biologic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Biologic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Biologic Drugs Sales Value Share by Type (2021-2032) Figure 23. Auto-Immune Diseases Image Figure 24. Inflammation Image Figure 25. Blood Diseases Image Figure 26. Cardiovascular Diseases Image Figure 27. Diabetes Image Figure 28. Others Image Figure 29. Global Biologic Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Biologic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 31. Global Biologic Drugs Sales Volume Share by Application (2021-2032) Figure 32. Global Biologic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Biologic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 34. Global Biologic Drugs Sales Value Share by Application (2021-2032) Figure 35. Global Biologic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 36. Global Biologic Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 37. Global Biologic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 38. Global Biologic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 39. North America Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. North America Biologic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Europe Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Europe Biologic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Asia-Pacific Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Asia-Pacific Biologic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. South America Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 46. South America Biologic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 47. Middle East & Africa Biologic Drugs Sales Value (2021-2032) & (US$ Million) Figure 48. Middle East & Africa Biologic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 49. USA Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. USA Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. USA Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Canada Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Canada Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Canada Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Mexico Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Mexico Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Mexico Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Germany Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Germany Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Germany Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. France Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. France Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. France Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. U.K. Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. U.K. Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. U.K. Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Italy Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Italy Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Italy Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Spain Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Spain Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Spain Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Russia Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Russia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Russia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Netherlands Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Netherlands Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Netherlands Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Nordic Countries Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Nordic Countries Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Nordic Countries Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. China Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. China Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. China Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Japan Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Japan Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Japan Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. South Korea Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. South Korea Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. South Korea Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. India Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. India Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. India Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Australia Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Australia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Australia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Southeast Asia Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Southeast Asia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Southeast Asia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Brazil Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Brazil Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Brazil Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Argentina Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Argentina Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Argentina Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Chile Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Chile Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Chile Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Colombia Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Colombia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Colombia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Peru Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Peru Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Peru Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Saudi Arabia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Saudi Arabia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Israel Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Israel Arabia Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Israel Arabia Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. UAE Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. UAE Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. UAE Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Turkey Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Turkey Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Turkey Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Iran Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Iran Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Iran Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Egypt Biologic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 131. Egypt Biologic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 132. Egypt Biologic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 133. Biologic Drugs Value Chain Figure 134. Manufacturing Cost Structure Figure 135. Biologic Drugs Sales Mode & Process Figure 136. Direct Comparison with Distribution Share Figure 137. Distributors Profiles Figure 138. Years Considered Figure 139. Research Process Figure 140. Key Executives Interviewed

Scope & coverage.

Types
  • Humira
  • Avastin
  • Enbrel
  • Herceptin
  • Lantus
  • Remicade
  • Rituxan
  • Others
Applications
  • Auto-Immune Diseases
  • Inflammation
  • Blood Diseases
  • Cardiovascular Diseases
  • Diabetes
  • Others
Companies covered
  • Abbott Laboratories
  • Amgen
  • Amgen
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck & Co.
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologic Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Biologic Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Biologic Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biologic Drugs Market Dynamics
  1. 2.1 Biologic Drugs Industry Trends
  2. 2.2 Biologic Drugs Industry Drivers
  3. 2.3 Biologic Drugs Industry Opportunities and Challenges
  4. 2.4 Biologic Drugs Industry Restraints
3 Biologic Drugs Market by Company
  1. 3.1 Global Biologic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Biologic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Biologic Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Biologic Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Biologic Drugs Company Ranking (2024-2026)
  6. 3.6 Global Biologic Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Biologic Drugs Company Product Type and Application
  8. 3.8 Global Biologic Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biologic Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biologic Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biologic Drugs Market by Type
  1. 4.1 Biologic Drugs Type Introduction
  2. 4.1.1 Humira
  3. 4.1.2 Avastin
  4. 4.1.3 Enbrel
  5. 4.1.4 Herceptin
  6. 4.1.5 Lantus
  7. 4.1.6 Remicade
  8. 4.1.7 Rituxan
  9. 4.1.8 Others
  10. 4.2 Global Biologic Drugs Sales Volume by Type
  11. 4.2.1 Global Biologic Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Biologic Drugs Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Biologic Drugs Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Biologic Drugs Sales Value by Type
  15. 4.3.1 Global Biologic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Biologic Drugs Sales Value by Type (2021-2032)
  17. 4.3.3 Global Biologic Drugs Sales Value Share by Type (2021-2032)
5 Biologic Drugs Market by Application
  1. 5.1 Biologic Drugs Application Introduction
  2. 5.1.1 Auto-Immune Diseases
  3. 5.1.2 Inflammation
  4. 5.1.3 Blood Diseases
  5. 5.1.4 Cardiovascular Diseases
  6. 5.1.5 Diabetes
  7. 5.1.6 Others
  8. 5.2 Global Biologic Drugs Sales Volume by Application
  9. 5.2.1 Global Biologic Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Biologic Drugs Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Biologic Drugs Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Biologic Drugs Sales Value by Application
  13. 5.3.1 Global Biologic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Biologic Drugs Sales Value by Application (2021-2032)
  15. 5.3.3 Global Biologic Drugs Sales Value Share by Application (2021-2032)
6 Biologic Drugs Regional Sales and Value Analysis
  1. 6.1 Global Biologic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Biologic Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Biologic Drugs Sales by Region (2027-2032)
  5. 6.3 Global Biologic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biologic Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biologic Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biologic Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Biologic Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biologic Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Biologic Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biologic Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Biologic Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biologic Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biologic Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biologic Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Biologic Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biologic Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biologic Drugs Sales Value Share by Country, 2025 VS 2032
7 Biologic Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Biologic Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biologic Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Biologic Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Biologic Drugs Sales by Country (2027-2032)
  6. 7.4 Global Biologic Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biologic Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biologic Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biologic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biologic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biologic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biologic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biologic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biologic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biologic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biologic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biologic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biologic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biologic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biologic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biologic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biologic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biologic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biologic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biologic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biologic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biologic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biologic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biologic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biologic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biologic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biologic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biologic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biologic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biologic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biologic Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biologic Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biologic Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biologic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories Biologic Drugs Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Biologic Drugs Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Biologic Drugs Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Biologic Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Biologic Drugs Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Biologic Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Merck & Co.
  38. 8.7.1 Merck & Co. Company Information
  39. 8.7.2 Merck & Co. Business Overview
  40. 8.7.3 Merck & Co. Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co. Biologic Drugs Product Portfolio
  42. 8.7.5 Merck & Co. Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Biologic Drugs Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson Biologic Drugs Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Biologic Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Biologic Drugs Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologic Drugs Value Chain Analysis
  2. 9.1.1 Biologic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologic Drugs Sales Mode & Process
  6. 9.2 Biologic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologic Drugs Distributors
  9. 9.2.3 Biologic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst